Perspectives on Enquiry & Evidence
The world's leading supplier of statistical insight to decision-makers in the lifesciences brings you debate and discussion of the newest trends in statistics and quantitative strategy.
September 4, 2015
Using Simulation for Accelerated Early Phase Drug Development
Our Client's Challenge: Can knowledge of the relationship between biomarkers and clinical endpoints help us to optimize..
Read article
April 23, 2015
Dose-finding with Sequential Parallel Comparison Designs
Last week the Cytel Blog discussed the benefits of using the Adaptive Maximizing Design [AM Design] for dose-finding..
Read article
December 16, 2014
Cultivating Versatility in Statistical Consultants
Richard Branson once wrote: “I have always valued capability over expertise. While you may need to hire specialists for..
Read article
October 14, 2014
7 Reasons to Add a Statistical Consultant to Your Team
We are often asked how statistical consultants can add value to the clinical development process. What do they..
Read article
October 7, 2014
You Own This!
Guest blogger Laurie Halloran is the President and CEO of Halloran Consulting Group, a management consulting firm for..
Read article
September 25, 2014
Part II: The Philosophy Behind a Software Package
A few weeks ago, we posted a synopsis of an event held at ISCB Vienna in which statisticians from Cytel, SAS and..
Read article
September 18, 2014
5 times ‘Keep it Simple’ May Be Bad Advice for Clinical Designers
When designing clinical trials, many trial designers are advised to keep the trial simple. Prima facie, the keep it..
Read article
July 22, 2014
10 Simple Steps to Deciding Whether Your Next Trial Should be Adaptive
PROCYSBI, the first drug to receive FDA approval after following an adaptive population re-assessment design, was one..
Read article